February 10, 2021– While hospitals across the country have been struggling to stay afloat and serve the health needs of a nation during a historic pandemic, one of the largest drug companies in the U.S. has been boosting its already huge profits by denying safety-net providers the drug discounts that the 340B drug pricing program requires. Two new reports show that as drug … [Read more...]
Senate Report Blasts Insulin Makers for High Prices
January 21, 2021– A new, bipartisan report from a key congressional committee is sharply critical of the three major drug manufacturers that sell insulin in the U.S. The companies – Eli Lilly, Novo Nordisk, and Sanofi – already have been all over the news recently for their pricing behavior. They also are the ringleaders of a group of drug companies that are circumventing … [Read more...]